3-(2-(pyrrolidin-1-yl)ethyl)-1H-indol-4-ol | 63097-26-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-(2-(pyrrolidin-1-yl)ethyl)-1H-indol-4-ol
• 英文别名: 3-<2-(1-Pyrrolidino)-ethyl>-indol-4-ol；3-(2-pyrrolidin-1-yl-ethyl)-indol-4-ol；4-HO-pyr-T；3-(2-pyrrolidin-1-ylethyl)-1H-indol-4-ol
• CAS: 63097-26-7
• 化学式: C₁₄H₁₈N₂O
• 分子量: 230.31
• InChiKey: XASLPZWIPBCAPF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  39.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(2-(pyrrolidin-1-yl)ethyl)-1H-indol-4-ol 在 potassium fluoride 、 N,N-硫酰二咪唑 、 三氟乙酸 作用下， 以 二氯甲烷 、 水 为溶剂， 以19%的产率得到3-(2-(pyrrolidin-1-yl)ethyl)-1H-indol-4-yl sulfurofluoridate
  参考文献：
  名称：

  [EN] METHOD OF SYNTHESIZING INDOLE COMPOUNDS
  [FR] PROCÉDÉ DE SYNTHÈSE DE COMPOSÉS D'INDOLE

  摘要：

  一种合成吲哚类化合物的方法。该方法可能包括联烯化吲哚化合物，氧化得到α-吲哚丙烯，还原胺化得到吲哚乙醛，从而提供色胺。吲哚化合物可能在吲哚环上被取代具有功能基团，或者可能是未取代的吲哚。该方法可能包括对吲哚化合物、色氨酸、色胺或中间体的吲哚环进行取代、氧化或其他衍生反应。该方法可能包括氧化色氨酸或环取代的色氨酸类似物，并还原胺化得到吲哚乙醛，从而提供色胺。该方法可能采用望远镜式的方法进行，而无需分离中间体。该方法可能应用于吲哚、α-吲哚丙烯、吲哚丙基二醇、吲哚乙醛和色胺的生产。本文还提供了每个类别化合物的化合物。

  公开号：

  WO2022140844A1
• 作为产物：
  描述：

  4-苄氧基吲哚 在 palladium on activated charcoal lithium aluminium tetrahydride 、 氢气 作用下， 生成 3-(2-(pyrrolidin-1-yl)ethyl)-1H-indol-4-ol
  参考文献：
  名称：

  SAR of psilocybin analogs: Discovery of a selective 5-HT2C agonist

  摘要：

  An SAR study of psilocybin and psilocin derivatives reveals that 1-methylpsilocin is a selective agonist at the h5-HT2C receptor. The corresponding phosphate derivative, 1-methylpsilocybin, shows efficacy in an animal model for obsessive-compulsive disorder, as does 4-fluoro-N,N-dimethyltryptamine. These results suggest a new area for development of novel 5-HT2C agonists with applications for drug discovery. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.06.104

文献信息

• H-D Exchange of Psilocin and Its Analogs
  作者：Haruhisa Shirahama、Kazuyo Sogawa、Kimiko Hashimoto

  DOI：10.3987/com-98-s(h)87

  日期：——
• COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID
  申请人：CaaMTech, LLC

  公开号：US20190142851A1

  公开（公告）日：2019-05-16

  This disclosure pertains to new compositions and methods comprising a psilocybin derivative. In one embodiment, the compositions disclosed herein are used for a method of regulating a neurotransmitter receptor, e.g., a serotonin receptor. In one embodiment, the compositions disclosed herein comprise purified compounds, e.g., a purified psilocybin derivative, a purified cannabinoid, or purified terpene.
• COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND
  申请人：CAAMTECH, INC.

  公开号：US20210346346A1

  公开（公告）日：2021-11-11

  Disclosed herein are compositions comprising a serotonergic tryptamine compound, combinations thereof, and methods of using them for treating and preventing a variety of human conditions. In one embodiment, disclosed herein are new compositions and methods which comprise a therapeutically effective amount of a first purified psilocybin derivative and a therapeutically effective amount of a second compound. The second compound is selected from the group consisting of a second purified psilocybin derivative, a purified terpene, a serotonergic drug, an adrenergic drug, a dopaminergic drug, a purified erinacine, and a purified hericenone.
• [EN] COMPOSITIONS AND METHODS FOR TREATING MIGRAINE<br/>[FR] COMPOSITIONS ET MÉTHODES DE TRAITEMENT DE LA MIGRAINE
  申请人：[en]WESANA HEALTH INC.

  公开号：WO2022115798A2

  公开（公告）日：2022-06-02

  As described below, the present disclosure features compositions containing a cannabidiol (CBD) and/or psilocybin, optionally in combination with a mushroom blend. The present disclosure also features methods for treating or preventing migraine, or symptoms thereof, with a cannabidiol and/or psilocybin, optionally in combination with a mushroom blend. The present disclosure also features compositions and methods of using psilocybin in combination with a neurotransmitter activity modulator for the treatment of neurological conditions (e.g., migraine), or symptoms thereof (e.g., anxiety or depression).
• SAR of psilocybin analogs: Discovery of a selective 5-HT2C agonist
  作者：Howard Sard、Govindaraj Kumaran、Cynthia Morency、Bryan L. Roth、Beth Ann Toth、Ping He、Louis Shuster

  DOI：10.1016/j.bmcl.2005.06.104

  日期：2005.10

  An SAR study of psilocybin and psilocin derivatives reveals that 1-methylpsilocin is a selective agonist at the h5-HT2C receptor. The corresponding phosphate derivative, 1-methylpsilocybin, shows efficacy in an animal model for obsessive-compulsive disorder, as does 4-fluoro-N,N-dimethyltryptamine. These results suggest a new area for development of novel 5-HT2C agonists with applications for drug discovery. (c) 2005 Elsevier Ltd. All rights reserved.